Skip to main content
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Sponsored By
Series
Series
A Dose Escalation Strategy for HR+/HER2− Early Breast Cancer: An Educational Video Series
Multiple Myeloma Education
ESMO Early Breast Cancer
ADC Therapy Treatment HER2+ and HER2-Low mBC
IWTI Best Practices in GU Navigation
Antibody Drug Conjugate Therapy for the Treatment of HER2+ and HER2-Low mBC
A Dose Escalation Strategy for HR+/HER2− Early Breast Cancer: An Educational Video Series
A Dose Escalation Strategy for HR+/HER2− Early Breast Cancer: An Educational Video Series
Interview with the Innovators
Improving Abemaciclib Tolerability: Insights From the TRADE Dose-Escalation Study
Jamie Carroll, APRN, CNP, MSN
Read More
A Dose Escalation Strategy for HR+/HER2− Early Breast Cancer: An Educational Video Series
Interview with the Innovators
Managing Abemaciclib Side Effects: Practical Tips for Improving Patient Care
Jamie Carroll, APRN, CNP, MSN
Read More
A Dose Escalation Strategy for HR+/HER2− Early Breast Cancer: An Educational Video Series
Interview with the Innovators
Managing Abemaciclib Toxicity: Proactive Strategies for Improved Patient Outcomes
Heather Moore, PharmD, BCOP, CPP
Read More
A Dose Escalation Strategy for HR+/HER2− Early Breast Cancer: An Educational Video Series
Interview with the Innovators
Insights From the TRADE Study: Optimizing Abemaciclib Dose Escalation for Better Tolerability and Adherence
Heather Moore, PharmD, BCOP, CPP
Read More
A Dose Escalation Strategy for HR+/HER2− Early Breast Cancer: An Educational Video Series
Interview with the Innovators
TRADE Study Insights: A New Approach to Improve Abemaciclib Tolerability in Breast Cancer Care
Erica Mayer, MD, MPH
Read More
A Dose Escalation Strategy for HR+/HER2− Early Breast Cancer: An Educational Video Series
Interview with the Innovators
Optimizing Adjuvant Abemaciclib: Insights From the TRADE Study on Dose Escalation and Tolerability
Erica Mayer, MD, MPH
Read More
Results 1 - 6 of 6
